Anhui Anke BioTech Group

Price Chart

Risk-Adjusted Performance

Anhui Anke BioTech Group (300009) Price Performance

Anhui Anke BioTech Group (300009) trades on SHE in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY9.75, down 1.22% from the previous close.

Over the past year, 300009 has traded between a low of CNY7.87 and a high of CNY12.30. The stock has gained 23.1% over this period. It is currently 20.7% below its 52-week high.

Anhui Anke BioTech Group has a market capitalization of $16.50B, with a price-to-earnings ratio of 22.43 and a dividend yield of 2.51%.

About Anhui Anke BioTech Group

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, immunohistochemical, sperm DNA fragmentation staining, leptin, and immunohistochemical diagnostic kits. In addition, it offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care products, including anti-aging, masks, essential liquids, and mouthwash; and sybthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, the company provides autosomal, sex chromosome, and other kits; paternity testing, tumor biological immunotherapy technology, and DNA testing services. Additionally, the company offers monoclonal antibody drugs, such as Trastuzumab to treat patients with breast and gastric cancers under the ANTRASTUIN brand; Bevacizumab, an anti-VFDF product; ANKEBIO anti-PD1; and anti-covid19 products. The company was founded in 2000 and is based in Hefei, China.

Compare Anhui Anke BioTech Group

Side-by-side comparison against top Healthcare peers.